Clinical Trials at Parkland Memorial Hospital
As of July 2026, 27 paid clinical trials are recruiting at Parkland Memorial Hospital, located at 5323 HARRY HINES BLVD, DEPT OF ORHTO SURGERY-UTSW MED CENTER, DALLAS, TX 75390-8870, phone (214) 648-4712 in Dallas, Texas. Active studies at this site cover conditions such as Breast Cancer, Heart Failure and Obesity. Compensation typically covers time, travel, and study visits — most studies also offer study-related medical care at no cost to participants.
Recruiting trial data synced daily from ClinicalTrials.gov. Last sync: .
Filter results
27 clinical trials at Parkland Memorial Hospital
·Clear filters·Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
Sickle Cell Kidney Biorepository
Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
Ketamine in Severe Traumatic Brain Injury
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
Common conditions studied in Dallas
- Breast Cancer (33 active studies)
- Heart Failure (32 active studies)
- Obesity (22 active studies)
- Advanced Solid Tumor (20 active studies)
- Prostate Cancer (20 active studies)
- Endometrial Cancer (16 active studies)
Leading research sponsors in Dallas
- University of Texas Southwestern Medical Center
- Baylor Research Institute
- AstraZeneca
- Eli Lilly and Company
- National Cancer Institute (NCI)
Frequently asked questions
How many paid clinical trials are currently recruiting in Dallas?
There are approximately 1,543 recruiting clinical trials in Dallas, Texas listed on ClinicalTrials.gov. The number changes weekly as new studies open and others close enrollment.
Do clinical trials in Dallas pay participants?
Most recruiting trials in Dallas compensate participants for their time, travel, and study visits. Compensation varies by sponsor, study phase, and visit requirements — the exact amount is disclosed by the study team during the informed consent process.
Who can participate in a clinical trial in Dallas?
Eligibility depends on the specific study. Each trial defines its own inclusion criteria (age, diagnosis, medical history, prior treatments) and exclusion criteria. Both patients with specific conditions and healthy volunteers can qualify, depending on the study design.
What conditions are most commonly studied in Dallas?
The most common conditions under active study in Dallas include Breast Cancer (33), Heart Failure (32), Obesity (22), Advanced Solid Tumor (20), among many others. Browse the list above to explore every recruiting trial.
Are there clinical trials for healthy volunteers in Dallas?
Yes. Healthy-volunteer studies — often early-phase pharmacology or vaccine trials — recruit in Dallas on an ongoing basis. Use the "Healthy volunteers only" filter above to view trials that accept participants without the study's target condition.
How do I enroll in a clinical trial in Dallas?
Click any study title above to see the full study record, including eligibility criteria, visit schedule, and the study team's contact information. Reach out to the central contact or recruiting site directly — they will guide you through screening and informed consent.
Where can I take part in paid clinical trials in Dallas?
Recruiting research sites in Dallas include University of Texas Southwestern Medical Center, UT Southwestern Medical Center, UT Southwestern/Simmons Cancer Center-Dallas, among others. Each site lists its open studies and contact information on the study record above — call or email the site coordinator to ask about screening for a specific protocol.
What kinds of studies are recruiting in Dallas right now?
The largest active categories in Dallas are Cancer & tumors (435), Cardiovascular (123), Neurology & pain (77). Use the filters above to narrow by therapeutic area, phase, age, or healthy-volunteer eligibility.
What is the address of Parkland Memorial Hospital?
Parkland Memorial Hospital is located at 5323 HARRY HINES BLVD, DEPT OF ORHTO SURGERY-UTSW MED CENTER, DALLAS, TX 75390-8870. Use the Google Maps link in the intro above to get directions.
How do I contact Parkland Memorial Hospital?
You can reach Parkland Memorial Hospital by phone at (214) 648-4712. For questions about a specific trial, use the study coordinator contact listed on the individual study record — click any trial title above to open it.